Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

197 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Assessing Lymphatic Uptake of Lipids Using Magnetic Resonance Imaging: A Feasibility Study in Healthy Human Volunteers with Potential Application for Tracking Lymph Node Delivery of Drugs and Formulation Excipients.
Jewell A, Williams H, Hoad CL, Gellert PR, Ashford MB, Butler J, Stolnik S, Scurr D, Stocks MJ, Marciani L, Gowland PA, Gershkovich P. Jewell A, et al. Pharmaceutics. 2021 Aug 27;13(9):1343. doi: 10.3390/pharmaceutics13091343. Pharmaceutics. 2021. PMID: 34575420 Free PMC article.
Patient and Public Involvement and Engagement in the Development of a Platform Clinical Trial for Parkinson's Disease: An Evaluation Protocol.
Zeissler ML, Bakshi N, Bartlett M, Batla A, Byrom D, Chapman R, Collins S, Cowd E, Deeson E, Ellis-Doyle R, Forbes J, Gonzalez-Robles C, Jewell A, Lane EL, LaPelle NR, Martin K, Matthews H, Miller L, Mills G, Morgan A, Parry M, Pushparatnam K, Ratcliffe N, Salathiel D, Scurfield P, Siu C, Whipps S, Wonnacott S, Foltynie T, Carroll CB, McFarthing K; EJS ACT-PD consortium. Zeissler ML, et al. Among authors: jewell a. J Parkinsons Dis. 2024 Apr 27. doi: 10.3233/JPD-230444. Online ahead of print. J Parkinsons Dis. 2024. PMID: 38701161
Evaluation of Homologous Recombination Deficiency in Ovarian Cancer.
Ratnaparkhi R, Javellana M, Jewell A, Spoozak L. Ratnaparkhi R, et al. Among authors: jewell a. Curr Treat Options Oncol. 2024 Feb;25(2):237-260. doi: 10.1007/s11864-024-01176-6. Epub 2024 Feb 1. Curr Treat Options Oncol. 2024. PMID: 38300479 Review.
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Moore KN, et al. N Engl J Med. 2023 Dec 7;389(23):2162-2174. doi: 10.1056/NEJMoa2309169. N Engl J Med. 2023. PMID: 38055253 Clinical Trial.
Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).
Arend RC, Monk BJ, Shapira-Frommer R, Haggerty AF, Alvarez EA, Amit A, Alvarez Secord A, Muller C, Casado Herraez A, Herzog TJ, Tewari KS, Cohen JG, Huang M, Yachnin A, Holeman LL, Ledermann JA, Rachmilewitz Minei T, Buyse M, Fain Shmueli S, Lavi M, Harats D, Penson RT; OVAL/GOG-3018 Investigators. Arend RC, et al. J Clin Oncol. 2024 Jan 10;42(2):170-179. doi: 10.1200/JCO.22.02915. Epub 2023 Oct 31. J Clin Oncol. 2024. PMID: 37906726 Clinical Trial.
197 results